Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Disclosure statements are available on the authors' profiles:
Nivolumab Plus Ipilimumab Versus Sunitinib for First-Line Treatment of Advanced Renal Cell Carcinoma: Extended 4-Year Follow-Up of the Phase III CheckMate 214 TrialESMO Open 2020 Nov 01;5(6)e001079, L Albiges, NM Tannir, M Burotto, D McDermott, ER Plimack, P Barthélémy, C Porta, T Powles, F Donskov, S George, CK Kollmannsberger, H Gurney, MO Grimm, Y Tomita, D Castellano, BI Rini, TK Choueiri, SS Saggi, MB McHenry, RJ Motzer
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.